Mizuho Medy Co.,Ltd.
Stock Price Chart
2026/08/12 UpdatedPrice Trend
2026/08/12 UpdatedPrice & Trading Details
2026/08/12 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/09| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥50 | -50.0% |
| 2025 | ¥100 | 0.0% |
| 2024 | ¥100 | 0.0% |
| 2023 | ¥100 | -20.0% |
| 2022 | ¥125 | - |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥17,582M | ¥10,989M | ¥11,429M | ¥11,260M |
| Gross Profit | ¥14,100M | ¥8,074M | ¥8,083M | ¥7,819M |
| Operating Income | ¥11,104M | ¥5,156M | ¥4,922M | ¥4,653M |
| Pretax Income | ¥11,104M | ¥5,156M | ¥4,922M | ¥4,653M |
| Net Income | ¥7,838M | ¥3,774M | ¥3,773M | ¥3,425M |
| EPS | ¥411.47 | ¥198.13 | ¥198.12 | - |
| Operating Margin | 63.16% | 46.92% | 43.07% | 41.32% |
| Balance Sheet | ||||
| Total Assets | ¥19,102M | ¥18,948M | ¥20,729M | ¥22,375M |
| Total Equity | ¥14,283M | ¥15,674M | ¥17,352M | ¥18,683M |
| Total Liabilities | ¥4,819M | ¥3,274M | ¥3,377M | ¥3,692M |
| Cash | ¥8,702M | ¥10,134M | ¥11,246M | ¥10,825M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 74.77% | 82.72% | 83.71% | 83.50% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥6,173M | ¥3,991M | ¥3,348M | ¥1,956M |
| Investing CF | -¥1,554M | -¥270M | -¥307M | -¥7,284M |
| Financing CF | -¥1,571M | -¥2,381M | -¥2,094M | -¥2,077M |
| Free CF | ¥5,993M | ¥3,722M | ¥3,049M | ¥1,673M |
| Efficiency | ||||
| ROE | 54.88% | 24.08% | 21.74% | 18.33% |
| ROA | 41.03% | 19.92% | 18.20% | 15.31% |
Latest IR Information
-
Mizuho Medy Co., Ltd. 2026 Fiscal Year 12 December Quarter 2 Interim Earnings Report
Interim period of the 2026 fiscal year, 2Q Interim Earnings Report. Discloses trends in revenue and profit, financial position, segment-by-segment status, and revenue breakdown over the last five business years. Also describes sales of COVID-19 related diagnostic tests, product line...
Read more -
Notice Regarding Dividends of Retained Earnings (Interim Dividend)
As an interim dividend, 50 yen per share, total dividend of 952 million yen to be paid on September 11, 2026. Payout ratio policy is 50%, implemented with consideration of earnings and financial position. Record date is June 30, 2026;...
Read more -
Financial Summary
Presenting the results for the 2Q26 and full-year guidance, along with future growth strategies. Disclosure of revenue and profit trends, segment-by-segment status, outlook, and risk factors.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,700
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid amplification test products comprising gene analysis instruments and mycoplasma pneumoniae nucleic acid kits. It also provides rapid immunoassay products, including influenza virus antigen test kit; RS virus and human metapneumovirus antigen test kit; streptococcus pneumoniae antigen and legionella antigen test kit; mycoplasma pneumoniae antigen test kit; adenovirus antigen test kit; rotavirus and adenovirus antigen test kit ;norovirus antigen test kit; Group A streptococcal antigen test kit; pregnancy test kit; ovulation test kit; and fecal occult blood test kit for in vitro diagnostic use. In addition, it offers reagents for detection in research and agriculture use; and reagents for biochemical test. Further, the company engages in import and export activities. It operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, and internationally. Mizuho Medy Co.,Ltd. was incorporated in 1977 and is headquartered in Tosu, Japan.
